12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ICT-107: Completed Phase II enrollment

ImmunoCellular said it completed enrollment of 278 newly diagnosed GBM patients in a double-blind, placebo-controlled, U.S. Phase IIb trial evaluating ICT-107. The company said the...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >